Diagnosing coinfection in pneumonia can be challenging because of timing of the sample collection and false-negative results when the viruses replicate in the lower respiratory tract.
Members of the PRISM trial group investigated whether CPAP administered immediately after major abdominal surgery could prevent postoperative morbidity.
Investigators conducted a quasi-experimental, retrospective study of adult patients with COVID-19 pneumonia to evaluate antibiotic use for community-acquired bacterial pneumonia following the release of guidelines.
Researchers compared trends in antibiotic prescription rates during the period preceding the pneumococcal conjugate vaccine (PCV), as well as the early and late PCV periods, among Jewish vs Bedouin children.
Researchers assessed antibiotic de-escalation practices across hospitals and their associations with outcomes in hospitalized patients with pneumonia who have negative cultures.
The vaccine contains capsular polysaccharide conjugates for 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) that cause invasive pneumococcal disease.
Researchers report findings from SAATELLITE, a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that assessed the safety and efficacy of suvratoxumab for Staphylococcus aureus pneumonia.
Treatment with tocilizumab did not lead to improvement in clinical status and did not lower mortality at 28 days compared with placebo in hospitalized patients with severe pneumonia related to COVID-19.
Investigators assessed the cumulative incidence of acute cardiovascular complications during hospitalization for community-acquired pneumonia in internal medicine units.
The objective of this quasi-experimental observational study was to measure the effect of states’ hospital worker influenza vaccination laws on pneumonia and influenza mortality.
Findings from a retrospective chart review showed a need to carefully monitor inflammatory biomarkers and anticoagulant dosage in patients with severe COVID-19.
The REMDACTA study evaluated the efficacy and safety of tocilizumab plus remdesivir in hospitalized patients with severe COVID-19 pneumonia receiving standard of care.
There appears to be a low risk of invasive fungal secondary infection, especially aspergillosis, in patients with SARS-CoV-2-related pneumonia and no underlying immunosuppression.
